Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer
Purpose: To establish the feasibility and efficacy of chemotherapy with capecitabine, weekly irinotecan, cetuximab, and pelvic radiotherapy for patients with locally advanced rectal cancer. Methods and materials: Twenty patients with rectal cancer (clinical Stage uT3-T4 or N+) received a standard do...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
18 September 2006
|
| In: |
International journal of radiation oncology, biology, physics
Year: 2006, Jahrgang: 66, Heft: 5, Pages: 1384-1390 |
| ISSN: | 1879-355X |
| DOI: | 10.1016/j.ijrobp.2006.07.005 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ijrobp.2006.07.005
|
| Verfasserangaben: | Ralf-Dieter Hofheinz, Karoline Horisberger, Christoph Woernle, Frederik Wenz, Uta Kraus-Tiefenbacher, Georg Kähler, Dietmar Dinter, Rainer Grobholz, Steffen Heeger, Stefan Post, Andreas Hochhaus, and Frank Willeke |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1793951683 | ||
| 003 | DE-627 | ||
| 005 | 20220820135434.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220225s2006 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijrobp.2006.07.005 |2 doi | |
| 035 | |a (DE-627)1793951683 | ||
| 035 | |a (DE-599)KXP1793951683 | ||
| 035 | |a (OCoLC)1341445473 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Hofheinz, Ralf-Dieter |d 1969- |e VerfasserIn |0 (DE-588)121917517 |0 (DE-627)08161876X |0 (DE-576)292991568 |4 aut | |
| 245 | 1 | 0 | |a Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer |c Ralf-Dieter Hofheinz, Karoline Horisberger, Christoph Woernle, Frederik Wenz, Uta Kraus-Tiefenbacher, Georg Kähler, Dietmar Dinter, Rainer Grobholz, Steffen Heeger, Stefan Post, Andreas Hochhaus, and Frank Willeke |
| 264 | 1 | |c 18 September 2006 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.02.2022 | ||
| 520 | |a Purpose: To establish the feasibility and efficacy of chemotherapy with capecitabine, weekly irinotecan, cetuximab, and pelvic radiotherapy for patients with locally advanced rectal cancer. Methods and materials: Twenty patients with rectal cancer (clinical Stage uT3-T4 or N+) received a standard dosing regimen of cetuximab (400 mg/m(2) on Day 1 and 250 mg/m(2) on Days 8, 15, 22, and 29) and escalating doses of irinotecan and capecitabine according to phase I methods: dose level I, irinotecan 40 mg/m(2) on Days 1, 8, 15, 22, and 29 and capecitabine 800 mg/m(2) on Days 1-38; dose level II, irinotecan 40 mg/m(2) and capecitabine 1000 mg/m(2); and dose level III, irinotecan 50 mg/m(2) and capecitabine 1000 mg/m(2). Radiotherapy was given to a dose of 50.4 Gy (45 Gy plus 5.4 Gy). Resection was scheduled 4-5 weeks after termination of chemoradiotherapy. Results: On dose level I, no dose-limiting toxicities occurred; however, Grade 3 diarrhea affected 1 of 6 patients on dose level II. Of 5 patients treated at dose level III, 2 exhibited dose-limiting toxicity (diarrhea in 2 and nausea/vomiting in 1). Therefore, dose level II was determined as the recommended dose for future studies. A total of 10 patients were treated on dose level II and received a mean relative dose intensity of 100% of cetuximab, 94% of irinotecan, and 95% of capecitabine. All patients underwent surgery. Five patients had a pathologically complete remission and six had microfoci of residual tumor only. Conclusion: Preoperative chemoradiotherapy with cetuximab, capecitabine, and weekly irinotecan is feasible and well tolerated. The preliminary efficacy is very promising. Larger phase II trials are ongoing. (c) 2006 Elsevier Inc. | ||
| 650 | 4 | |a 5-fluorouracil | |
| 650 | 4 | |a adjuvant therapy | |
| 650 | 4 | |a capecitabine | |
| 650 | 4 | |a carcinomas | |
| 650 | 4 | |a cetuximab | |
| 650 | 4 | |a chemoradiation | |
| 650 | 4 | |a fluorouracil | |
| 650 | 4 | |a irinotecan | |
| 650 | 4 | |a leucovorin | |
| 650 | 4 | |a local-control | |
| 650 | 4 | |a locally advanced rectal cancer | |
| 650 | 4 | |a plus irinotecan | |
| 650 | 4 | |a preoperative chemoradiotherapy | |
| 650 | 4 | |a radiation-therapy | |
| 650 | 4 | |a radiotherapy | |
| 700 | 1 | |a Horisberger, Karoline |d 1974- |e VerfasserIn |0 (DE-588)129014850 |0 (DE-627)387770240 |0 (DE-576)297447602 |4 aut | |
| 700 | 1 | |a Woernle, Christoph |d 1980- |e VerfasserIn |0 (DE-588)140127526 |0 (DE-627)616037309 |0 (DE-576)314701753 |4 aut | |
| 700 | 1 | |a Wenz, Frederik |d 1966- |e VerfasserIn |0 (DE-588)113310390 |0 (DE-627)663837766 |0 (DE-576)346656281 |4 aut | |
| 700 | 1 | |a Kraus-Tiefenbacher, Uta |d 1969- |e VerfasserIn |0 (DE-588)1013173406 |0 (DE-627)704975718 |0 (DE-576)346656990 |4 aut | |
| 700 | 1 | |a Kähler, Georg |d 1957- |e VerfasserIn |0 (DE-588)1026227925 |0 (DE-627)726295515 |0 (DE-576)371525020 |4 aut | |
| 700 | 1 | |a Dinter, Dietmar |d 1968- |e VerfasserIn |0 (DE-588)138698813 |0 (DE-627)605258139 |0 (DE-576)308596269 |4 aut | |
| 700 | 1 | |a Grobholz, Rainer |e VerfasserIn |0 (DE-588)1068350679 |0 (DE-627)820163538 |0 (DE-576)427721032 |4 aut | |
| 700 | 1 | |a Heeger, Steffen |d 1969- |e VerfasserIn |0 (DE-588)123499828 |0 (DE-627)706322142 |0 (DE-576)293735034 |4 aut | |
| 700 | 1 | |a Post, Stefan |d 1954- |e VerfasserIn |0 (DE-588)1026227518 |0 (DE-627)726294667 |0 (DE-576)371524598 |4 aut | |
| 700 | 1 | |a Hochhaus, Andreas |d 1959- |e VerfasserIn |0 (DE-588)1107039339 |0 (DE-627)863321976 |0 (DE-576)474976130 |4 aut | |
| 700 | 1 | |a Willeke, Frank |d 1963- |e VerfasserIn |0 (DE-588)1084359758 |0 (DE-627)848798902 |0 (DE-576)170761568 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of radiation oncology, biology, physics |d Amsterdam [u.a.] : Elsevier Science, 1975 |g 66(2006), 5, Seite 1384-1390 |h Online-Ressource |w (DE-627)306659662 |w (DE-600)1500486-7 |w (DE-576)081986319 |x 1879-355X |7 nnas |a Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer |
| 773 | 1 | 8 | |g volume:66 |g year:2006 |g number:5 |g pages:1384-1390 |g extent:7 |a Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijrobp.2006.07.005 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220225 | ||
| 993 | |a Article | ||
| 994 | |a 2006 | ||
| 998 | |g 1084359758 |a Willeke, Frank |m 1084359758:Willeke, Frank |d 910000 |d 910200 |e 910000PW1084359758 |e 910200PW1084359758 |k 0/910000/ |k 1/910000/910200/ |p 12 |y j | ||
| 998 | |g 1107039339 |a Hochhaus, Andreas |m 1107039339:Hochhaus, Andreas |d 60000 |d 61200 |e 60000PH1107039339 |e 61200PH1107039339 |k 0/60000/ |k 1/60000/61200/ |p 11 | ||
| 998 | |g 1026227518 |a Post, Stefan |m 1026227518:Post, Stefan |d 60000 |d 61800 |e 60000PP1026227518 |e 61800PP1026227518 |k 0/60000/ |k 1/60000/61800/ |p 10 | ||
| 998 | |g 1068350679 |a Grobholz, Rainer |m 1068350679:Grobholz, Rainer |d 60000 |e 60000PG1068350679 |k 0/60000/ |p 8 | ||
| 998 | |g 138698813 |a Dinter, Dietmar |m 138698813:Dinter, Dietmar |d 60000 |d 62900 |e 60000PD138698813 |e 62900PD138698813 |k 0/60000/ |k 1/60000/62900/ |p 7 | ||
| 998 | |g 1026227925 |a Kähler, Georg |m 1026227925:Kähler, Georg |p 6 | ||
| 998 | |g 1013173406 |a Kraus-Tiefenbacher, Uta |m 1013173406:Kraus-Tiefenbacher, Uta |d 60000 |d 63000 |e 60000PK1013173406 |e 63000PK1013173406 |k 0/60000/ |k 1/60000/63000/ |p 5 | ||
| 998 | |g 113310390 |a Wenz, Frederik |m 113310390:Wenz, Frederik |d 60000 |d 63000 |d 60000 |e 60000PW113310390 |e 63000PW113310390 |e 60000PW113310390 |k 0/60000/ |k 1/60000/63000/ |k 0/60000/ |p 4 | ||
| 998 | |g 140127526 |a Woernle, Christoph |m 140127526:Woernle, Christoph |d 60000 |d 61800 |e 60000PW140127526 |e 61800PW140127526 |k 0/60000/ |k 1/60000/61800/ |p 3 | ||
| 998 | |g 129014850 |a Horisberger, Karoline |m 129014850:Horisberger, Karoline |d 60000 |d 61800 |e 60000PH129014850 |e 61800PH129014850 |k 0/60000/ |k 1/60000/61800/ |p 2 | ||
| 998 | |g 121917517 |a Hofheinz, Ralf-Dieter |m 121917517:Hofheinz, Ralf-Dieter |d 60000 |d 61200 |e 60000PH121917517 |e 61200PH121917517 |k 0/60000/ |k 1/60000/61200/ |p 1 |x j | ||
| 999 | |a KXP-PPN1793951683 |e 4073562959 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Hofheinz","given":"Ralf-Dieter","display":"Hofheinz, Ralf-Dieter","role":"aut"},{"family":"Horisberger","display":"Horisberger, Karoline","given":"Karoline","role":"aut"},{"display":"Woernle, Christoph","given":"Christoph","family":"Woernle","role":"aut"},{"role":"aut","display":"Wenz, Frederik","given":"Frederik","family":"Wenz"},{"role":"aut","display":"Kraus-Tiefenbacher, Uta","given":"Uta","family":"Kraus-Tiefenbacher"},{"role":"aut","family":"Kähler","given":"Georg","display":"Kähler, Georg"},{"role":"aut","family":"Dinter","display":"Dinter, Dietmar","given":"Dietmar"},{"role":"aut","display":"Grobholz, Rainer","given":"Rainer","family":"Grobholz"},{"role":"aut","display":"Heeger, Steffen","given":"Steffen","family":"Heeger"},{"family":"Post","display":"Post, Stefan","given":"Stefan","role":"aut"},{"role":"aut","family":"Hochhaus","display":"Hochhaus, Andreas","given":"Andreas"},{"given":"Frank","display":"Willeke, Frank","family":"Willeke","role":"aut"}],"recId":"1793951683","name":{"displayForm":["Ralf-Dieter Hofheinz, Karoline Horisberger, Christoph Woernle, Frederik Wenz, Uta Kraus-Tiefenbacher, Georg Kähler, Dietmar Dinter, Rainer Grobholz, Steffen Heeger, Stefan Post, Andreas Hochhaus, and Frank Willeke"]},"origin":[{"dateIssuedKey":"2006","dateIssuedDisp":"18 September 2006"}],"language":["eng"],"title":[{"title_sort":"Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer","title":"Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer"}],"physDesc":[{"extent":"7 S."}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"doi":["10.1016/j.ijrobp.2006.07.005"],"eki":["1793951683"]},"relHost":[{"title":[{"subtitle":"the official journal of the American Society for Therapeutic Radiology and Oncology","title_sort":"International journal of radiation oncology, biology, physics","title":"International journal of radiation oncology, biology, physics"}],"origin":[{"publisher":"Elsevier Science","dateIssuedDisp":"1975-","dateIssuedKey":"1975","publisherPlace":"Amsterdam [u.a.]"}],"note":["Gesehen am 15.01.20","Ungezählte Beil.: Supplement"],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1500486-7"],"issn":["1879-355X"],"eki":["306659662"]},"part":{"issue":"5","extent":"7","volume":"66","text":"66(2006), 5, Seite 1384-1390","pages":"1384-1390","year":"2006"},"language":["eng"],"disp":"Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancerInternational journal of radiation oncology, biology, physics","recId":"306659662","pubHistory":["1.1975/76 -"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"note":["Gesehen am 25.02.2022"]} | ||
| SRT | |a HOFHEINZRAPHASEITRIA1820 | ||